The bill S. 5383 proposes to classify two substances, MGM-15 and MGM-16, as Schedule I controlled substances under the Controlled Substances Act. Additionally, it seeks to categorize synthetic 7-hydroxymitragynine and Mitragynine Pseudoindoxyl as Schedule I controlled substances as well. This classification indicates that these substances are considered to have a high potential for abuse and no accepted medical use.
Supporters of the bill argue that scheduling these substances is necessary to protect public health and safety. They highlight concerns about the potential for abuse and addiction associated with synthetic derivatives of kratom and other related substances, emphasizing the need for regulatory oversight.
Critics of the bill contend that scheduling these substances could hinder research and limit access to potential therapeutic benefits. They argue that the decision is driven by fear rather than scientific evidence, and express concerns about the implications for individuals who use these substances for pain management or other health issues.
The analysis of bill S. 5383, which seeks to classify MGM-15, MGM-16, synthetic 7-hydroxymitragynine, and Mitragynine Pseudoindoxyl as Schedule I controlled substances, reveals no direct industry overlaps with the sponsor Bernie Moreno's top donor industries. The primary donor industries, Health Professionals and Retired, have contributed significant amounts—$360 million and $112.5 million respectively—but neither appears to have a vested interest in the regulation of the substances mentioned in the bill. This lack of overlap suggests that the motivations behind the bill are not financially influenced by the sponsor's top donors, indicating a low risk of conflict of interest. Voters should be aware that while the financial contributions are substantial, they do not directly relate to the subject matter of the bill, which mitigates potential concerns about undue influence.
Top industries funding Bernie Moreno, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
